Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Souvenaid

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand

The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...

Impetus Digital

Another Landmark Lucid Workiversary

We’re celebrating another landmark Workiversary with Richard Barry, Senior Medical Writer. Richard has now been a Lucidian for an impressive 10 years, so we thought it was only fitting to...

Lucid Group Communications Limited

- PMLiVE

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone

- PMLiVE

Recruiting patients for real-world studies – the power of a digital campaign

By Will Maier

- PMLiVE

Biogen and Eisai present new data for controversial Alzheimer’s drug Aduhelm at AAIC

The data showed that high-dose Aduhelm treatment demonstrated consistent effects as measured by the Clinical Dementia Rating-Sum of Boxes

- PMLiVE

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen will gain antibody technologies designed to discover and develop new molecules with broad applications across therapeutic areas

Employee wellbeing in creative agencies: three tips to get you started

Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration

Fox&Cat

Managing unhelpful pressure in your creative agency: the human approach

Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?

Fox&Cat

- PMLiVE

AbbVie reveals new data for presbyopia eye drop treatment

Opthalmic solution is currently being reviewed by the US Food and Drug Administration

- PMLiVE

The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model

By Siobhan Reilly

Biogen Idec building

Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate

The phase 1b study demonstrated an encouraging safety and tolerability profile in patients with mild Alzheimer’s disease

- PMLiVE

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a bid to protect Remicade

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links